For the Inventor, By the Inventor

Enter assignee name

Fremont, CA, United States of America

Quark Pharmaceuticals, Inc.

USPTO Granted Patents = 67

% Expired Patents = 74.6

CIPO Patents = 10

EPO Patents = 25

Forward Citations = 386

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Elena Feinstein (56 out of 74 patents)

Igor Mett (21 out of 44 patents)

Hagar Kalinski (17 out of 25 patents)

4. Sharon Avkin-Nachum (16 out of 21 patents)

5. Svetlana Adamsky (6 out of 6 patents)

6. Igor Spivak (6 out of 6 patents)

7. Rami Skaliter (6 out of 12 patents)

8. Shai Erlich (5 out of 8 patents)

9. Evgenia Alpert (5 out of 6 patents)

10. Amir Bar-Ilan (5 out of 5 patents)

11. Shai Ehrlich (5 out of 5 patents)

12. Klaus Giese (4 out of 28 patents)

13. Jörg Kaufmann (4 out of 33 patents)

14. James D Thompson (3 out of 3 patents)

15. Daniel Zurr (3 out of 3 patents)

Core Competencies:

Oligonucleotide Compounds

siRNA Therapies

Neuroprotection

Lung Disease Treatments

RTP801 Inhibitors

CASP2 Targeting

Eye Disorder Treatments

Fibrotic Conditions

Gene Modulation

Acute Renal Failure

Ischemia-Reperfusion Injury

Cancer Treatments

67 patents: Sort by Forward Citations

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),

2. 10570394 - Double-stranded RNA compounds to CASP2 and uses thereof (2020-02-25),

3. 10494631 - siRNA compounds comprising terminal substitutions (2019-12-03),

4. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),

5. 10144928 - Double stranded oligonucleotide compounds comprising positional modifications (2018-12-04),

6. 9993567 - Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases (2018-06-12),

7. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),

8. 9868953 - Methods and compositions for preventing ischemia reperfusion injury in organs (2018-01-16),

9. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),

10. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),

11. 9738896 - Methods and compositions for neuroprotection (2017-08-22),

12. 9701961 - Methods for treating eye disorders (2017-07-11),

13. 9701960 - siRNA compounds comprising terminal substitutions (2017-07-11),

14. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),

15. 9611473 - Double-stranded nucleic acid compounds (2017-04-04),

Quark Pharmaceuticals, Inc., based in Fremont, CA, specializes in the development of innovative oligonucleotide therapeutics. The company focuses on harnessing the potential of siRNA therapies to address a range of medical conditions, including neuroprotection, lung diseases, and various eye disorders. Quark's research emphasizes the modulation of specific biological pathways, such as RTP801 inhibition and CASP2 targeting, to create effective treatments for fibrotic conditions and other serious health issues.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

67 Patents

#40 in Fremont, CA

#1,267 in California

#5,451 in US

#11,018 in the World

Fremont, CA, United States of America

Quark Pharmaceuticals, Inc.

Forward Citations = 386

40 inventors:

Elena Feinstein (56 out of 74 patents)

Igor Mett (21 out of 44 patents)

Hagar Kalinski (17 out of 25 patents)

4. Sharon Avkin-Nachum (16 out of 21 patents)

5. Svetlana Adamsky (6 out of 6 patents)

Please report any incorrect information to [email protected]

Loading…